Stockscreener 앱 받기
4.24
0.24%
-0.010
시간 외 거래:
4.25
0.010
+0.24%
전일 마감가:
$4.25
열려 있는:
$4.223
하루 거래량:
3,685
Relative Volume:
0.03
시가총액:
$2.83M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00506
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
-2.53%
1개월 성능:
+4.69%
6개월 성능:
-75.13%
1년 성능:
-89.84%
1일 변동 폭
$4.22
$4.35
1주일 범위
$4.1372
$4.6289
52주 변동 폭
$3.50
$74.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
BDRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
4.24 | 2.83M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-08 | 개시 | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: A Year of Declines and Increases - The InvestChronicle
Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News
Interim results for the six months ended June 30, 2024 - StockTitan
Market Watch Highlights: Biodexa Pharmaceuticals Plc ADR (BDRX) Ends on an Downturn Note at 0.29 - The Dwinnex
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
ADR Ratio Change - Markets Insider
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
Biodexa secures full access to cancer research grant - Investing.com
BDRX Stock on the Rise: A Promising Investment - The InvestChronicle
Financial Health Report: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios Tell a Tale - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Investors in cash trouble should check out Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals Plc ADR (BDRX) is a good investment, but the stock may be undervalued - US Post News
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan
Stocks of Biodexa Pharmaceuticals Plc ADR (BDRX) are poised to climb above their peers - SETE News
BDRXBiodexa Pharmaceuticals plc American Depositary Shs Latest Stock News & Market Updates - StockTitan
Biodexa’s eRapa Shows Promise in FAP Treatment - TipRanks
12 ChatGPT Penny Stock Picks Right Now - Insider Monkey
Biodexa Pharmaceuticals Regains Nasdaq Compliance - Investing.com India
Biodexa Pharmaceuticals will rise 8,000% at the open - Dhaka Tribune
Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.49%
0.79%
자본화:
|
볼륨(24시간):